Shares of GRAIL plunged 8.3% to $68.00 in after-hours trading following a second-quarter report that, on the surface, looked strong — revenue of $44.7 million marked a 26% year-over-year jump — but left investors questioning whether the company is sacrificing price to chase volume. GRAIL Sold More Cancer Tests Than Ever, but a Quiet Price Squeeze Has Investors Asking Whether Volume Alone Can Justify the Valuation
Shares of GRAIL cratered 8.3% to $68.00 in after-hours trading on August 5, even as the cancer-detection company posted a second-quarter revenue beat. Total revenue grew 26% year-over-year to $44.7 million, with its flagship multi-cancer blood test generating $42.6 million of that total. The headline numbers looked healthy. The market's reaction says investors are looking deeper.
- Volume Is Surging, but Each Test Is Bringing In Less Money. Test volume jumped 35% year-over-year to more than 61,000. Yet test revenue grew only 24% — an 11-percentage-point gap that reveals falling average selling prices. Simple math: revenue per test dropped from roughly $760 a year ago to about $698 this quarter. The list price remains $949 , but a reduced self-pay price of $799 or less is available through many providers , and employer and insurance channels likely push realized pricing even lower. For a company still deeply unprofitable, shrinking revenue per unit is a red flag.
- Losses Remain Enormous Relative to Revenue. The net loss for the quarter was $110.2 million, with a gross loss of $12.6 million — meaning GRAIL spent more to deliver and process its tests than it collected in revenue. The selloff appears rooted in investors questioning how long they must wait for revenue to outweigh the losses.
- The FDA Clock Is Ticking, and That's the Real Bet. Management expects an FDA advisory committee meeting this fall and still anticipates potential approval in the first part of 2027. Formal FDA clearance would unlock insurance reimbursement and dramatically change the economics. The test is not currently covered by Medicare or most health insurance plans , meaning virtually every sale today is out-of-pocket. Without approval, volume growth will keep requiring price concessions.
- A Samsung Deal Buys Time, but Dilutes Existing Holders. GRAIL closed a $110 million equity financing with Samsung , opening international commercialization discussions in South Korea, Japan, and Singapore. But the share count swelled to 44.7 million from 40.3 million at year-end 2025 — roughly 11% dilution in six months. Cash on hand stands at $861.6 million, providing runway, but shareholders are paying for it.
The bottom line: GRAIL is selling more cancer tests than ever, but until FDA approval flips the business model from consumer-pay to insurer-pay, every new sale may come at a thinner margin — and investors just showed they're running out of patience.